Outcome of adult patients with JIA treated with the biosimilar Benepali
Benepali®
Biosimilar
Effectiveness
Enbrel®
Etanercept
Juvenile idiopathic arthritis
Therapy survival
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
13 12 2022
13 12 2022
Historique:
received:
17
12
2021
accepted:
02
12
2022
entrez:
13
12
2022
pubmed:
14
12
2022
medline:
16
12
2022
Statut:
epublish
Résumé
To analyze therapy adherence, safety, and outcome in adult patients with juvenile idiopathic arthritis (JIA) treated with the etanercept biosimilar Benepali Data from the prospective registry, JuMBO (Juvenile arthritis MTX/Biologics long-term Observation), were used for the analysis. JuMBO is a long-term observational cohort study. It follows adult patients with JIA who were formerly included in the national JIA biologic register (BiKeR Registry). Both registries provide individual trajectories of clinical data and outcomes from childhood to adulthood in JIA patients treated with disease-modifying anti-rheumatic drugs (DMARDs). Eighty-three patients from the German JuMBO registry were treated with Benepali Tolerability and effectiveness of the biosimilar Benepali
Sections du résumé
BACKGROUND
To analyze therapy adherence, safety, and outcome in adult patients with juvenile idiopathic arthritis (JIA) treated with the etanercept biosimilar Benepali
METHODS
Data from the prospective registry, JuMBO (Juvenile arthritis MTX/Biologics long-term Observation), were used for the analysis. JuMBO is a long-term observational cohort study. It follows adult patients with JIA who were formerly included in the national JIA biologic register (BiKeR Registry). Both registries provide individual trajectories of clinical data and outcomes from childhood to adulthood in JIA patients treated with disease-modifying anti-rheumatic drugs (DMARDs).
RESULTS
Eighty-three patients from the German JuMBO registry were treated with Benepali
CONCLUSIONS
Tolerability and effectiveness of the biosimilar Benepali
Identifiants
pubmed: 36514116
doi: 10.1186/s13075-022-02968-7
pii: 10.1186/s13075-022-02968-7
pmc: PMC9746218
doi:
Substances chimiques
Etanercept
OP401G7OJC
Biosimilar Pharmaceuticals
0
Antirheumatic Agents
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
271Informations de copyright
© 2022. The Author(s).
Références
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1703-9
pubmed: 24980508
Arthritis Rheum. 1980 Feb;23(2):137-45
pubmed: 7362664
Z Rheumatol. 2013 May;72(4):339-46
pubmed: 23456365
Ann Rheum Dis. 2004 Dec;63(12):1638-44
pubmed: 15115709
ACR Open Rheumatol. 2020 Jan;2(1):37-47
pubmed: 31943968
Ann Rheum Dis. 2009 Apr;68(4):519-25
pubmed: 18413440
Arthritis Res Ther. 2016 Nov 24;18(1):272
pubmed: 27881144
ACR Open Rheumatol. 2021 Nov;3(11):779-787
pubmed: 34449981
Arthritis Care Res (Hoboken). 2019 Apr;71(4):471-481
pubmed: 30044538
Arthritis Res Ther. 2020 Oct 29;22(1):258
pubmed: 33121528
Rheumatol Ther. 2016 Dec;3(2):187-207
pubmed: 27747582
Rheumatology (Oxford). 2012 Aug;51(8):1407-15
pubmed: 22447885
Z Rheumatol. 2020 Dec;79(10):983-995
pubmed: 33258976
Rheumatol Ther. 2019 Sep;6(3):317-338
pubmed: 31385263
Arthritis Care Res (Hoboken). 2017 Apr;69(4):552-560
pubmed: 27390133
Rheumatology (Oxford). 2017 Aug 1;56(suppl_4):iv30-iv48
pubmed: 28903543
RMD Open. 2019 Aug 12;5(2):e001016
pubmed: 31452931
Arthritis Care Res (Hoboken). 2015 Nov;67(11):1529-35
pubmed: 25988824
Arthritis Rheum. 2009 May 15;61(5):658-66
pubmed: 19405003
Arthritis Rheumatol. 2018 Sep;70(9):1408-1418
pubmed: 29609207
Ann Rheum Dis. 2016 May;75(5):855-61
pubmed: 25926155
Ann Rheum Dis. 2019 Feb;78(2):192-200
pubmed: 30396903